Drug search by name

Cetuximab Intravenous and Platinol-AQ

Determining the interaction of Cetuximab Intravenous and Platinol-AQ and the possibility of their joint administration.

Check result:

Cetuximab Intravenous <> Platinol-AQ

Relevance: 10.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using cetuximab together with CISplatin and/or radiation may increase the risk of side effects such as painful mouth sores, acne-like skin rash, electrolyte imbalances, chest pain, irregular heart rhythm, and heart attack. Let your doctor know if you have a history of coronary artery disease, congestive heart failure, or other heart problems. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: The safety of cetuximab in combination with cisplatin and radiation therapy has not been established. Death and serious cardiotoxicity were observed in a single-arm trial with cetuximab, cisplatin (100 mg/m2), and delayed, accelerated (concomitant boost) fractionation radiation therapy conducted in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Two of 21 patients died, one from pneumonia and one from an unknown cause. Four patients discontinued treatment due to adverse events, two of which were cardiac events (myocardial infarction in one and arrhythmia, diminished cardiac output, and hypotension in the other). An integrated analysis across all clinical studies demonstrated that cisplatin does not affect the pharmacokinetics of cetuximab. In a controlled study of 940 patients with locally advanced SCCHN, the addition of cetuximab to cisplatin and radiation resulted in an increase in the incidence of grade 3 or 4 mucositis, radiation recall syndrome, acneiform rash, cardiac events, and electrolyte disturbances compared to radiation and cisplatin alone. Adverse reactions with fatal outcome were reported in 4.4% versus 3.0%, and myocardial ischemia in 2.0% versus 0.9%, of patients in the cetuximab combination arm compared to the control arm. The addition of cetuximab to radiation and cisplatin did not improve progression-free survival.

MANAGEMENT: Until more data are available, caution is advised if cetuximab is used in combination with cisplatin and/or radiation, particularly in patients with a history of coronary artery disease, congestive heart failure, or arrhythmias. Patients should be monitored closely for cardiotoxicity, and therapy discontinued if necessary.

References

"Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb, Princeton, NJ.

Cetuximab Intravenous

Generic Name: cetuximab

Brand name: Erbitux

Synonyms: Cetuximab

What is Cetuximab Intravenous?

Platinol-AQ

Generic Name: cisplatin

Brand name: Platinol, Platinol-AQ

Synonyms: Platinol-AQ (Intravenous)

What is Platinol-AQ?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions